CDK4 and esophageal squamous cell carcinoma: As monotherapy of PI3Kα displayed limited benefit in ESCC patients, it is worthwhile to evaluate the safety and efficacy of the combined regimen with CDK4/6 inhibitors for the treatment of ESCC with proficient Rb.